The weight-loss drug market leader is renewing a focus on infectious-disease prevention.

Eli Lilly said it received positive results from its phase 1b clinical trials for its experimental gene editing treatment for high cholesterol. The pharmaceutical company said Monday that a single ...

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...

Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

The pharma giant is taking steps to expand its portfolio.

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs ...

In an early-stage trial, one infusion of the therapy resulted in reduced PCSK9 levels by up to 88% and LDL cholesterol by up ...

(Reuters) -Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into ...

The disclosure forms bear Trump’s signature. They show seven purchases of Lilly stock made on the president’s behalf through ...